Arbutus Biopharma Corp.

These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.

Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.

How the share price reacted

Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.

What Arbutus Biopharma Corp. does

AB-101 is an oral PD-L1 inhibitor candidate that is designed to allow for controlled checkpoint blockade while minimizing the systemic safety issues typically seen with checkpoint antibody therapies. Immune checkpoints such as PD-1/PD-L1 play an important role in the induction and maintenance of immune tolerance and in T-cell activation, for example against hepatitis B virus (“HBV”). In Arbutus’ Phase 1a/1b clinical trial, AB-101 was generally well-tolerated with evidence of high receptor occupancy.

The company’s own description, as it appears at the foot of the release.